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Abstract
AIM
To investigate gender-specific liver estrogen receptor 
(ER) expression in normal subjects and patients 
with hepatitis C virus (HCV)-related cirrhosis and 
hepatocellular carcinoma (HCC).
METHODS
Liver tissues from normal donors and patients dia-
gnosed with HCV-related cirrhosis and HCV-related 
HCC were obtained from the NIH Liver Tissue and Cell 
Distribution System. The expression of ER subtypes, 
ERα and ERβ, were evaluated by Western blotting 
and real-time RT-PCR. The subcellular distribution of 
ERα and ERβ was further determined in nuclear and 
cytoplasmic tissue lysates along with the expression of 
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inflammatory [activated NF-κB and IκB-kinase (IKK)] 
and oncogenic (cyclin D1) markers by Western blotting 
and immunohistochemistry. The expression of ERα and 
ERβ was correlated with the expression of activated 
NF-κB, activated IKK and cyclin D1 by Spearman’s 
correlation. 
RESULTS
Both ER subtypes were expressed in normal livers but 
male livers showed significantly higher expression of 
ERα than females (P  < 0.05). We observed significantly 
higher mRNA expression of ERα in HCV-related HCC 
liver tissues as compared to normals (P  < 0.05) and 
ERβ in livers of HCV-related cirrhosis and HCV-related 
HCC subjects (P  < 0.05). At the protein level, there 
was a significantly higher expression of nuclear ERα 
in livers of HCV-related HCC patients and nuclear 
ERβ in HCV-related cirrhosis patients as compared 
to normals (P  < 0.05). Furthermore, we observed a 
significantly higher expression of phosphorylated NF-
κB and cyclin D1 in diseased livers (P  < 0.05). There 
was a positive correlation between the expression 
of nuclear ER subtypes and nuclear cyclin D1 and a 
negative correlation between cytoplasmic ER subtypes 
and cytoplasmic phosphorylated IKK in HCV-related 
HCC livers. These findings suggest that dysregulated 
expression of ER subtypes following chronic HCV-
infection may contribute to the progression of HCV-
related cirrhosis to HCV-related HCC.
CONCLUSION
Gender differences were observed in ERα expression 
in normal livers. Alterations in ER subtype expression 
observed in diseased livers may influence gender-
related disparity in HCV-related pathogenesis.
Key words: Estrogen receptor α; Estrogen receptor β; 
Hepatitis C virus-related cirrhosis; Hepatitis C virus-
related hepatocellular carcinoma; Sex and gender; 
Normal liver
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Core tip: Our study, for the first time, demonstrates 
gender-based differences in basal expression of 
estrogen receptor α (ERα) in the liver of normal males 
and females. Altered nuclear and cytoplasm liver 
ER subtype protein expression was also observed 
in hepatitis C virus (HCV)-cirrhosis and HCV-related 
hepatocellular carcinoma (HCC) that correlate with the 
inflammatory and oncogenic markers, activated NF-κB 
and cyclin D1, implicating their role in chronic cirrhosis 
and malignant transformation. These findings may 
have an impact on future planning strategies for the 
development of novel treatments or prognostic markers 
by targeting ERs or their signaling pathways during 
chronic HCV-related cirrhosis and HCC development.
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INTRODUCTION
Hepatitis C virus (HCV) infection is a major health 
problem in the United States[1]. HCV-infection tends to 
be asymptomatic for long periods of time during which 
fibrosis and cirrhosis can develop, resulting in end-
stage liver disease[2,3]. No viable vaccine is currently 
available for HCV prevention and, while newer and 
expensive direct acting antivirals are available for 
treating early HCV-infection, transplantation is the only 
effective treatment for patients with advanced or end 
stage liver disease[4,5]. HCV-infection related fibrosis 
and cirrhosis are associated with the development 
of chronic liver disease that eventually leads to 
hepatocellular carcinoma (HCC), the most common 
type of liver cancer[6-8]. The latest epidemiological data 
shows that HCC has the fastest growing death rate in 
the United States[9]. Thus, there is an urgent need to 
develop novel, effective and affordable therapeutics to 
treat chronic HCV-infections.
Understanding the contribution of host factors 
that directly or indirectly interact with HCV is central 
to finding new treatment modalities[10]. Striking 
gender disparity in HCV and HCC pathogenesis has 
led to the investigation of estrogen as one of the 
key host players in modulating the course of HCV-
pathogenesis. Epidemiological and clinical studies 
have shown that chronic HCV-infections are more 
prevalent in males and progress more rapidly to 
cancer development as compared to females[11,12]. 
Similar to males, postmenopausal females lacking 
circulating estrogen show accelerated progression of 
HCV-infection to fibrosis and HCC development[12,13]. 
In contrast, physiological estrogen levels seen in 
premenopausal females, have been associated with 
less severity and slow progression through all stages of 
HCV infection[11,14]. Direct evidence of the therapeutic 
potential of estrogen has come from experimen-
tal studies demonstrating that administration of 
17β-estradiol inhibits HCC development in in vitro 
and in vivo animal models[15,16]. However, clinical trials 
evaluating hormonal therapy using selective estrogen 
receptor modulators (SERMs) have shown inconsistent 
outcomes in HCC patients[17-19]. These inconsistencies 
may be attributed to the differences in the expression 
of estrogen receptors (ERs) in the liver[20].  
Liver is a sexually dimorphic organ and expresses 
the ERs, ERα and ERβ, making it responsive to the 
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actions of estrogen[21,22]. These receptors classically 
function as transcription factors, shuttling between the 
cytoplasm and nucleus for regulating the expression 
of various genes involved in cell cycle, proliferation, 
apoptosis and inflammation[23]. More recently, the 
non-classical role of ERs in cell signaling has become 
increasingly evident[24,25]. The two subtypes, ERα and 
ERβ share significant structural homology and ligand 
binding properties and yet function very differently, 
often antagonizing each other’s actions[26]. Thus, the 
relative expression of the two subtypes can have 
a significant impact on net cellular responses to 
estrogen. 
In breast cancer, ERα:ERβ expression ratio is 
thought to play a key role in estrogen-dependent 
tumor development[27,28]. Like breast cancer, aberrant 
increase in ER gene expression has been reported in 
liver tumors when compared to normal or non-tumor 
parts of the liver in HCC patients[29,30]. However, there 
is very limited information available on the relative 
expression of ERα and ERβ subtypes and ERα:ERβ 
expression ratio in livers of normals, HCV-related 
cirrhosis and HCV-related HCC. 
We hypothesized that basal liver ERα and ERβ 
expression differs in males vs females and this 
differential expression dictates host susceptibility 
to chronic HCV or its progression to hepatocellular 
carcinoma. In the present study, we evaluated the 
expression of ERα and ERβ in the livers of normals, 
HCV-cirrhosis and HCV-related HCC at the mRNA and 
protein levels using different techniques. We further 
determined the correlation of ER subtype expression 
with the levels of inflammatory and oncogenic markers 
like NF-κB and cyclin D1. Our findings show that the 
basal expression of ER subtypes is different between 
normal males and females. Furthermore, sub-cellular 
expression of both ER subtypes is altered in HCV 
cirrhosis and HCV-related HCC livers as compared 
to normals and correlates with the expression of 
inflammatory and oncogenic markers. This altered 
expression of ER subtypes in the liver may contribute 




Explant liver tissues from normal donors and HCV-
related cirrhosis and HCV-related HCC patients (Tables 
1-3) were obtained from the NIH Liver Tissue and 
Cell Distribution System (LTCDS) at the University of 
Minnesota. Liver explants were aseptically collected 
under the institutional review board (IRB) guidelines of 
University of Minnesota. The study was conducted at 
Oklahoma State University-Center for Health Sciences 
under IRB guidelines. In order to avoid interference 
of other co-factors, patients co-infected with human 
immunodeficiency virus (HIV) or hepatitis B virus (HBV) 
or with a history of alcohol consumption or drug use 
were excluded from the study. Liver explants were 
snap frozen in liquid nitrogen and stored at -80 ℃ until 
further use. 
Western blot analysis
Whole tissue lysates were prepared by homogenizing 
approximately 200 to 300 mg of liver tissues in liquid 
nitrogen followed by lysis in buffer comprising of 50 
mmol/L Tris-HCl (pH 8.0), 400 mmol/L KCl, 10 mmol/L 
EDTA, 2 mmol/L phenylmethylsulfonyl fluoride, 1 μg/
mL aprotinin and 1 μg/mL leupeptin. The homogenates 
were centrifuged at 30000 × g for 1 h at 4 ℃. The 
supernatants were collected and stored at -80 ℃ until 
further use. Cytoplasmic and nuclear fractions were 
prepared from liver tissues using the NE-PER kit (Pierce 
Chemical Co., Rockland, IL, United States) as per the 
manufacturer’s instructions. Protein concentrations 
were determined by Bicinchoninic acid assay (Pierce 
Chemical Co., Rockland, IL, United States). Thirty 
micrograms of protein from each lysate (whole 
tissue lysate, cytoplasmic or nuclear tissue lysates) 
was resolved on 4%-12% Bis-Tris Gel (Invitrogen, 
Carlsbad, CA, United States). The separated proteins 
were electrophoretically transblotted on to a 0.2 μm 
nitrocellulose membrane. Purified recombinant ERα 
and ERβ proteins were included as positive controls. 
The membrane was blocked in 5% non-fat dry milk 
made in TBS (20 mmol/L Tris-HCl, pH 7.6 and 136 
mmol/L NaCl) containing 0.1% Tween-20 for 2 h and 
probed with antibodies specific for human ERα (rat 
monoclonal against human ERα, H222, Fitzgerald 
Industries International Inc., Concord, MA, United 
States), human ERβ (mouse monoclonal against amino 
acids 1-153 of human ERβ, 14C8, Affinity Bioreagents, 
Golden, CO, United States), phosphorylated IκB-kinase 
(IKK) αβ (rabbit polyclonal against a phosphopeptide 
corresponding to amino acids surrounding Ser176/180 
of human IKKα, Cell signaling Technology, Danvers, 
MA, United States), IKKα (rabbit polyclonal against a 
peptide corresponding to 20 amino-terminal amino 
acids of human IKKα, Cell signaling Technology, 
Danvers, MA, United States), Cyclin D1 (rabbit 
polyclonal against amino acids 1-295 of human 
cyclin D1, H-295, Santa Cruz Biotechnology, Dallas, 
TX, United States), phosphorylated NF-κB (mouse 
monoclonal against a phosphopeptide corresponding 
to amino acids surrounding Ser536 of human NF-κB 
p65 subunit, Cell signaling Technology, Danvers, MA, 
United States), NF-κB (rabbit monoclonal against a 
peptide corresponding to amino acids near the amino-
terminus of human NF-κB p65 subunit, Cell signaling 
Technology, Danvers, MA, United States) and β-actin 
(rabbit polyclonal against a peptide corresponding to 
amino acid 20-33 of actin, Sigma-Aldrich, St. Louis, 
MO, United States). After incubation with alkaline 
phosphatase conjugated secondary antibodies (Sigma-
Aldrich, St. Louis, MO, United States), the protein 
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(Thermo Fisher Scientific, Waltham, MA, United 
States) followed by purification on RNeasy columns 
(Qiagen, Valencia, CA, United States) as per the 
manufacturer’s instructions. Total RNA from each sample 
was treated with DNase (Thermo Fisher Scientific, 
Waltham, MA, United States) and then reverse-
transcribed to synthesize cDNA using the High capacity 
cDNA synthesis kit (Applied Biosystems, Foster City, 
CA, United States). The expression of target genes 
was evaluated by quantitative real-time PCR using 
commercially available ERα and ERβ specific Taqman 
primers and probe assay mixes (Applied Biosystems, 
Foster City, CA, United States) on an ABI StepOne 
Real-Time PCR System (Applied Biosystems Foster 
City, CA, United States). Hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) was included 
as the endogenous control. Relative differences in 
gene expression between groups were determined 
using the 2-ΔΔCT method using the normal group for 
normalization[31].
Statistical analysis
The statistical methods of this study were performed 
and reviewed by Dr. Mark E. Payton from Department 
of Statistics, Oklahoma State University, Stillwater, 
United States. Data obtained from Western blotting 
and real time RT-PCR experiments were analyzed 
statistically using SAS software v9.4 (SAS Institute 
Inc., Cary, NC, United States). Statistical significance 
between appropriate groups was determined by 
non-parametric analyses that included the Kruskall-
Wallis test and Mann Whitney U  test. Post-hoc 
analyses were performed using Fisher’s Protected 
Least Significant Difference comparisons using rank 
data test. Correlations of ER subtypes with other 
proteins were analyzed by using the Spearman’s rank 
correlation test. P ≤ 0.05 was considered statistically 
significant. All graphs were made and depicted using 
the GraphPad Prism v6 software (GraphPad Software 
Inc, La Jolla, CA, United States). 
RESULTS
Basal expression of ERα is significantly higher in liver 
of normal males than females 
Due to the well-established gender disparity in HCC 
prevalence, we initiated this study by investigating 
the expression of ERα and ERβ in normal males 
and females. Whole tissue lysates of liver explants 
obtained from normal females and normal males 
(Table 1) were evaluated by Western blotting using 
validated ERα and ERβ directed antibodies (Figure 
1A). Densitometric analysis of protein bands showed 
comparable ER subtype expression in normal male and 
female tissues when the gender data was pooled (Figure 
1B).  However, when ER subtype expression data was 
segregated based on gender, we found that there was 
a significantly higher expression of ERα in males as 
bands were detected by enhanced chemiluminescence 
(Pierce Chemical Co., Rockland, IL, United States). To 
ensure the purity of cytoplasmic and nuclear fractions, 
the blots were also probed with anti-GAPDH (rabbit 
monoclonal against a peptide corresponding to a 
part of the carboxyl terminus of human GAPDH, Cell 
signaling Technology, Danvers, MA, United States) 
and anti-histone H1 (mouse monoclonal against nuclei 
from biopsies of myeloid leukemia cells, EMD Millipore, 
Billerica, MA, United States) antibodies respectively. 
Images of the protein bands were digitally captured 
with Alpha Innotech instrumentation (Alpha Innotech 
Corp, San Leandro, CA, United States) and quantified 
with Image analysis program, ImageJ (NIH, Bethesda, 
MD, United States). The phosphorylated forms were 
expressed as a ratio of the phosphorylated protein to 
total protein.
Immunohistochemistry
Immunohistochemistry was performed on normal 
and diseased explant liver tissue sections to confirm 
the protein expression of ERα, ERβ and cyclin D1. 
Formalin-fixed liver tissues were embedded in paraffin 
and sectioned into 4-μm thick sections. Non-enzymatic 
antigen retrieval was performed in citrate buffer 
(pH 6.0) using a microwave procedure. Slides were 
allowed to cool down for 20 min at room temperature 
and endogenous peroxidase was quenched with 
Dako EnVision system kit according to manufacturer’
s instructions (Dako, Carpintaria, CA, United States). 
The sections were washed and incubated for 30 min 
with 0.5% Triton X-100 in PBS followed by 5% rabbit 
serum. The tissue sections were incubated overnight 
with primary antibodies against ERα (rabbit polyclonal 
against a peptide corresponding to the carboxyl 
terminus of mouse ERα, MC-20, 1:50 dilution, Santa 
Cruz Biotechnology, Dallas, TX, United States), or ERβ 
(mouse monoclonal against peptide corresponding to 
the carboxyl terminus of ERβ, PPG5/10, 1:20 dilution, 
Dako, Carpinteria, CA, United States) at 4℃. Slides 
were washed with PBS containing 0.05% Tween 
and treated for one hour at room temperature with 
corresponding HRP labeled secondary antibodies (Dako, 
Carpinteria, CA, United States). The tissue sections 
were stained with 3,3’-diaminobenzidine and the nuclei 
were counterstained with Mayer’s hematoxylin. A 
similar immunostaining procedure was used for cyclin 
D1 (rabbit polyclonal antibody against amino acids 
1-295 of human cyclin D1, H-295, 1:150 dilution, 
Santa Cruz Biotechnology, Dallas, TX, United States). 
For negative controls, sections were incubated with 
PBS instead of the primary antibody. The stained 
sections were visualized using Nikon microscope (Nikon 
H600 L) and sections with staining of ≥ 10% of the 
cells were defined as positive.
Real-time RT-PCR
Total RNA was isolated from liver tissues with Trizol 
Iyer JK et al. ER expression in hepatitis C-mediated pathogenesis
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compared to females (Figure 1C). No difference was 
found in the expression of ERβ between males and 
females. Since physiological outcomes are determined 
by the expression of both, ERα and ERβ, we compared 
the ERα:ERβ expression ratio between male and 
females and found that males showed a significantly 
higher ERα:ERβ expression ratio compared to females 
(Figure 1D). 
Altered expression of ERα is observed in males with 
HCV-related cirrhosis and HCV-related HCC 
The expression of ER subtypes was compared in liver 
explants of normals, HCV-related cirrhosis and HCV-
related HCC (Tables 1 and 2) by real time RT-PCR and 
Western blotting (Figure 2). At the transcriptional level, 
there was an increase in the liver mRNA expression of 
ERα (ESR1) and ERβ (ESR2) subtypes in chronic HCV 
and HCV-related HCC as compared to normals (Figure 
2A and B). This change in expression significantly 
decreased the ER subtype ratio in the HCV-related 
cirrhosis group compared to normal (Figure 2C), 
suggesting that HCV infection may result in altering the 
expression of ER subtypes. 
When we measured ER subtype protein levels by 
Western blotting, we could not detect any significant 
differences among the three groups when the data 
was evaluated without gender segregation (Figure 2 
D-G). However, upon separating males and females, 
Table 1  Age ranges of normal and diseased subjects in whole 
tissue lysates










Normal 20 11 42-67 9 34-64
HCV 14  4 53-60 10 43-55
HCC 14  1 56 13 44-66
HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.
Table 2  Age ranges of normal and diseased subjects in 
mRNA analysis










Normal 9 8 42-67 1 64
HCV 10  3 43-60 7 43-53
HCC 10  0 N/A 10 44-59
HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.
Figure 1  Expression of estrogen receptor subtypes in whole tissue lysates from normal male and female subjects. A: Whole tissue lysates from liver tissues 
of normal donors were subjected to Western blotting and probed with antibodies against ERα, ERβ and β-actin. A representative blot is shown. B-D: The bands 
corresponding to ERα, ERβ and β-actin were quantified by densitometric analyses using ImageJ. Each symbol represents one individual. Expression of the ER 
subtypes was normalized to the expression of β-actin and plotted (B). Gender-based ER subtype expression was evaluated by segregating the gender and plotted (C). 
The ERα:ERβ expression ratio was also plotted for each gender group (D). aP < 0.05 was considered significant. ER: Estrogen receptor.










Table 3  Age ranges of normal and diseased subjects in 
nuclear and cytoplasmic tissue lysates 










Normal 10 5 43-67   5 50-64
HCV 12 3 51-60   9 46-53
HCC 16 0 NA 16 44-66
HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.
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Figure 2  Expression of estrogen receptor subtypes from normal and diseased subjects. A-C: Total RNA extracted from normal, HCV-related cirrhosis and 
HCV-related HCC livers was subjected to RT-PCR. The abundance of ESR1 (A) and ESR2 (B) transcripts was determined by real time PCR and normalized to 
the expression of HPRT. ESR1:ESR2 expression ratio was also plotted for the three groups (C). aP < 0.05 or bP < 0.001 was considered significant. D: Whole 
tissue lysates from liver tissues of normal, HCV and HCC subjects were subjected to Western blotting and probed with antibodies against ERα, ERβ and β-actin. 
Representative blots for each group are depicted. E-J: The bands corresponding to ERα, ERβ and β-actin were quantified by densitometric analyses using ImageJ. 
Expression of the ERα and ERβ was normalized to the expression of β-actin and plotted (E and F). The ERα:ERβ expression ratio was also plotted for normal, HCV 
and HCC group (G). Expression of ER subtypes and ERα:ERβ expression ratio in the male population of normal, HCV and HCC groups was plotted separately (H-J). 
aP < 0.05 was considered significant. HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; ER: Estrogen receptor.
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we observed a significant decrease in the expression of 
ERα in diseased livers (HCV as well as HCC) compared 
to normal livers (Figure 2H) but no difference in the 
expression of ERβ (Figure 2I) in males. This resulted in 
a significant decrease in ERα:ERβ expression ratio in 
male diseased livers (HCV as well as HCC) compared to 
normal male livers (Figure 2J). Among the females, we 
could compare the expression of ER subtypes between 
normals and HCV-related cirrhosis only as there were 
no females in the HCV-related HCC category. We found 
that there were no significant differences in protein 
levels of ERα and ERβ between normal livers and HCV-
related cirrhotic livers in females (Figure 2H and I). We 
further observed a positive-correlation between the 
expression of ERα and ERβ in HCV-related cirrhosis 
and HCV-related HCC group based on gender-pooled 
data (Table 4).
Thus the results from the mRNA and protein 
analyses performed in whole tissue extracts showed 
different trends. Since classical ERs shuttle between 
the nuclear and cytoplasmic compartments of the cells 
and mediate their regulatory functions by binding to 
estrogen response elements on DNA, we evaluated the 
expression of ER subtypes in nuclear and cytoplasmic 
extracts of liver tissues. 
Increased nuclear translocation of ER subtypes is 
observed in HCV-related cirrhosis and HCV-related HCC
The distribution and expression of ERα and ERβ in 
nuclear and cytoplasmic extracts of normal, HCV-
related cirrhosis and HCV-related HCC group is 
depicted in Figure 3. We observed a higher expression 
of ERα in the nuclear extracts of normal males as 
compared to normal females but the increase was 
not statistically significant, probably due to the small 
sample size (Supplementary Figure 1). There was 
no change in the expression of nuclear ERβ. These 
observations in normals for the expression of nuclear 
ERα and ERβ were similar to the results observed in 
whole tissue extracts.
When we compared the expression of ER subtypes 
in nuclear and cytoplasmic extracts of normal and 
diseased livers, we could not perform statistically 
relevant gender analyses due to the small sample size 
and scarcity of female subjects in the diseased groups. 
Hence we have reported our results without gender 
segregation. We observed a significant increase 
in the expression of nuclear ERα and ERβ in HCV-
related HCC and HCV-related cirrhosis (Figure 3A, 
B and D) respectively when compared to normals. 
However, there was no significant difference in the 
expression of cytoplasmic ERα, while HCV-related 
HCC group showed a significantly higher expression 
of cytoplasmic ERβ compared to HCV-related cirrhosis 
group (Figure 3C and E). An increase in the nuclear:
aP  < 0.05, bP  < 0.001, cP  < 0.055. HCV: Hepatitis C virus; HCC: 
Hepatocellular carcinoma; ER: Estrogen receptor.
aP < 0.05, bP < 0.001. HCV: Hepatitis C virus; HCC: Hepatocellular 
carcinoma; ER: Estrogen receptor.
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Table 5  Spearman correlations of ERα and ERβ expression 
in nuclear tissue lysates with nuclear cyclin D1 and nuclear 
phosphorylated NF-κB expression
r-coefficient (P  value)
Normal HCV HCC
Correlations with nuclear ERα
   Nuclear ERβ 0.63880 (0.0468)a 0.63539 (0.0264)a 0.73192 (0.0008)b
   Nuclear cyclin D1 0.12049 (0.7402) 0.75728 (0.0043)a 0.55714 (0.0202)a
   Nuclear pNF-κB -0.62968(0.0511)c 0.207 (0.5186) 0.4793 (0.0516)c
Correlations with nuclear ERβ
   Nuclear cyclin D1 0.44012 (0.2031) 0.64445 (0.0237)a 0.51223 (0.0355)a
   Nuclear pNF-κB -0.52091 (0.1226) 0.10243 (0.7514) 0.25861 (0.3162)
aP < 0.05, bP < 0.001. HCV: Hepatitis C virus; HCC: Hepatocellular 
carcinoma; ER: Estrogen receptor; WTL: Whole tissue lysates.
R-coefficient (P  value)
Normal HCV HCC
Correlations with WTL ERα
   ERβ 0.4154 (0.0692) 0.81944 (0.0006)b 0.70339 
(0.0107)a
   Nuclear cyclin D1 0.62189 (0.0549) 0.88842 (0.0075)a -0.29785 
(0.3737)
   Nuclear pNF-κB 0.02757 (0.9397) 0.84435 (0.0169)a 0.19351 
(0.5686)
   Cytoplasmic pIKK -0.21577 (0.5494) -0.09787 (0.8346) -0.37679 
(0.2534)
Correlations with WTL ERβ
   Nuclear cyclin D1 -0.03251 (0.9290) 0.92648 (0.0027)a -0.70135 
(0.0162)a
   Nuclear pNF-κB -0.18056 (0.6176) 0.71732 (0.0696) 0.41196 
(0.2080)
   Cytoplasmic pIKK 0.24608 (0.4931) -0.21801 (0.6386) -0.03438 
(0.9201)
Table 4  Spearman correlations of ERα and ERβ expression 
in whole tissue lysates with nuclear cyclin D1, nuclear 
phosphorylated NF-κB and cytoplasmic phosphorylated IKK 
expression
Table 6  Spearman correlations of ERα and ERβ expression in 
cytoplasmic tissue lysates with cytoplasmic pIKK
r-coefficient (P  value)
Normal HCV HCC
Correlations with cytoplasmic ERα
   Cytoplasmic ERβ 0.61233 (0.0599) 0.74376 (< 0.0001)a 0.79765 
(0.0158)b
   Cytoplasmic pIKK -0.66837 (0.0346)a -0.00698 (0.9828) -0.56014 
(0.0194)a
Correlations with cytoplasmic ERβ
   Cytoplasmic ERα 0.61233 (0.0599) 0.91363 (< 0.0001)b 0.79765 
(0.0001)b
   Cytoplasmic pIKK -0.60909 (0.0616) -0.29717 (0.3482) -0.60848 
(0.0095)a
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Figure 3  Expression of estrogen receptor subtypes in nuclear and cytoplasmic tissue lysates from normal and diseased subjects. A: Lysates prepared from 
nuclear and cytoplasmic fractions of liver tissues from normal, HCV and HCC subjects were subjected to Western blotting and probed with antibodies against ERα, 
ERβ, β-actin, histone (nuclear lysates only) and GAPDH (cytoplasmic lysates only). Representative blots for each group are depicted. B-G: The bands corresponding 
to ERα, ERβ and β-actin were quantified by densitometric analyses using ImageJ. Expression of the ERα and ERβ was normalized to the expression of β-actin and 
plotted with (B and C). The ERα:ERβ expression ratio was also plotted for normal, HCV and HCC group (D). Expression of ER subtypes and ERα:ERβ expression 
ratio in the male population of normal, HCV and HCC groups was plotted separately (E-G). aP < 0.05 or bP < 0.001 was considered significant. HCV: Hepatitis C virus; 
HCC: Hepatocellular carcinoma; ER: Estrogen receptor.
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cytoplasmic ratio of both, ERα and ERβ, in the diseased 
groups were observed compared to the normals 
(Supplementary Figure 1) suggesting that there is 
increased transcriptional activation of ER subtypes in 
the progression to HCV-related cirrhosis to HCV-related 
HCC. Furthermore, there was a significant increase in 
the ratio ERα:ERβ in the cytoplasmic compartment of 
the HCV-related cirrhosis and HCV-related HCC groups 
compared to normals (Figure 3G) but there was no 
significant difference in the ratio of the nuclear ER 
subtypes (Figure 3F). 
HCV-related cirrhosis and HCV-related HCC group show 
higher activation of NF-κB 
HCV infection is known to trigger inflammatory 
pathways and livers displaying chronic inflammation 
are more at risk of developing hepatocellular ca-
rcinoma[32,33]. Most inflammatory pathways involve NF-
κB, hence we evaluated the activation of the NF-κB 
signaling pathway by detecting the phosphorylation 
of the p65 subunit and IKK; the kinase that phos-
phorylates IκB, resulting in its dissociation from 
NF-κB and degradation by the proteasome. Livers 
chronically infected with HCV and HCV-related HCC 
tissues showed significantly higher expression of 
phosphorylated NF-κB (Figure 4A and B) compared 
to normals. There was an increase in the expression 
of pIKK from normal livers to HCV cirrhosis and HCV-
related HCC, but the increase was not statistically 
significant (Figure 4C). We also observed a weak 
negative correlation between nuclear ERα and pNF-
κB in normal liver tissues (r = -0.62968, P = 0.0511; 
Table 5). On the contrary, HCV-related HCC group 
demonstrated a weak positive correlation between 
nuclear ERα and pNF-κB (r = 0.4793, P = 0.0516; 
Table 5).  In addition, expression levels of pIKK and 
the cytoplasmic ER subtypes showed a strong negative 
correlation in the HCC group (ERα: r = -0.56014, P = 
0.0194; ERβ: r = -0.60848, P = 0.0095; Table 6).
ERα levels correlate with expression of cyclin D1 in both 
HCV cirrhosis and HCV-related HCC
In order to study the correlation of ERs with oncogenic 
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Figure 4  Expression of pNF-κB and pIKK in nuclear and cytoplasmic tissue lysates from normal and diseased subjects. A: Lysates prepared from nuclear 
and cytoplasmic fractions of liver tissues from normal, HCV and HCC subjects were subjected to Western blotting. Nuclear tissue lysates were probed with antibodies 
against pNF-κB, NF-κB, β-actin, and histones while cytoplasmic tissue lysates were probed with antibodies against pIKK, IKK, β-actin and GAPDH. Representative 
blots for each group are depicted. B and C: The bands corresponding to pNF-κB, NF-κB, pIKK, IKK and β-actin were quantified by densitometric analyses using 
ImageJ. The ratio of pNF-κB:NF-κB was normalized to the expression of β-actin and plotted (B). The ratio of pIKK:IKK was normalized to the expression of β-actin 
and plotted with gender pooled (C) subjects. aP < 0.05 was considered significant. HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; ER: Estrogen receptor.
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expression of cyclin D1 in the nuclear and cytoplasmic 
liver tissue extracts of normals, HCV-related cirrhosis 
and HCV-related HCC group by Western blotting 
(Table 3). As shown in Figure 5, there was a significant 
increase in the expression of cyclin D1 in both, 
the nuclear and cytoplasmic fractions of diseased 
livers, suggesting that chronic HCV infection primes 
hepatocytes to proliferate. A positive-correlation 
between the expression of nuclear ERα and ERβ with 
nuclear cyclin D1 was observed in both HCV-related 
cirrhosis (ERα: r = 0.75728, P = 0.0043; ERβ: r = 
0.64445, P = 0.0237; Table 5) and HCV-related HCC 
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Figure 5  Expression of cyclin D1 in nuclear and cytoplasmic tissue lysates from normal and diseased subjects. A: Lysates prepared from nuclear and 
cytoplasmic fractions of liver tissues from normal, HCV and HCC subjects were subjected to Western blotting and probed with antibodies against cyclin D1, β-actin, 
histones (nuclear lysates only) and GAPDH (cytoplasmic lysates only). Representative blots for each group are depicted. B and C: The bands corresponding to cyclin 
D1 and β-actin were quantified by densitometric analyses using ImageJ. Expression of cyclin D1 was normalized to the expression of β-actin in nuclear (B) and 
cytoplasmic (C) lysates and plotted. aP < 0.05 or bP < 0.001 was considered significant. D: Immunohistochemical staining of ERα, ERβ and cyclin D1 in normal (a, d, g), 
HCV-related cirrhosis (b, e, h) and HCV-related HCC (c, f, i) is depicted. A magnified region of the stained tissue section is depicted as an inset in each corresponding 
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(ERα: r = 0.55714, P = 0.0202; ERβ: r = 0.51223, P = 
0.0355; Table 5) groups but not in normals, signifying 
the importance of ER subtypes in cyclin D1 activation 
(Table 5). We further determined the expression of 
ER subtypes and cyclin D1 by immunohistochemistry 
(IHC). As observed with Western blotting, IHC showed 
over-expression of ERα and cyclin D1 in HCV-related 
cirrhosis and HCV-related HCC groups (Figure 5D, 
Supplementary Tables 1-3).  
DISCUSSION
Various epidemiological studies around the globe have 
recognized the role of gender bias in the progression 
of HCV infection to chronic liver disease and cirrhosis 
due to poor therapeutic responses or further 
development of HCV-related HCC in these patients[34]. 
Remarkable differences have been observed in 
the incidence, progression of HCV-related chronic 
liver disease and outcome of interferon therapy in 
males, postmenopausal females and premenopausal 
females[13,35]. This has generated a significant interest 
in the scientific community to investigate the role 
of estrogen as the key host factor in HCV-related 
pathogenesis. Recent studies in postmenopausal 
women with HCV-related fibrosis clearly show clinical 
benefits from estrogen replacement therapy in 
conjunction with standard HCV treatment[12]. One of 
the most compelling evidence is the inhibition of HCV 
life cycle by 17β-estradiol in an ERα dependent manner 
in human liver cell lines[36,37]. Raloxifene, a SERM, 
treatment has been shown to improve the efficacy of 
antiviral treatment in HCV-infected postmenopausal 
women[38]. These findings suggest a protective role of 
estrogen affecting not only viral replication but also 
HCV pathogenesis in the host.
Despite the recognition of estrogen as a potentially 
significant host factor in HCV pathogenesis, little 
progress has been made to understand the underlying 
mechanisms on how ER subtypes may be involved in 
progression to HCV chronic disease in some patients 
and rapid clearance of HCV in others. Perhaps this 
gap in understanding is one of the major factors 
contributing to the current debatable potential of 
estrogen therapy[17,19]. In addition, most of the clinical 
studies did not monitor ERα and ERβ expression in 
the liver of the enrolled patients or the hormonal 
status of females at the time of recruitment or during 
treatment[20]. Some studies evaluated ER subtype 
expression by measuring mRNA levels in the liver or 
performing less specific ligand binding assays[39, 40]. 
One of the most important premises of the current 
study was to evaluate the gender-based (males vs 
females) ER subtype protein expression in the liver 
of normals (basal expression) and further evaluate 
the changes in expression of these subtypes in HCV-
related cirrhosis or HCV-related HCC patients. Further, 
we employed subcellular fractionation (nuclear verses 
cytoplasmic) protein studies to examine the relative 
expression of ER subtypes and correlate their presence 
with activation of NF-κB or cyclin D1 in these fractions. 
Our findings in whole tissue extracts of normal livers 
indicated that males express significantly higher levels 
of ERα protein compared to females but comparable 
levels of ERβ. We also found a significant increase in 
the ERα:ERβ expression ratio in males as compared 
to females. To our knowledge, this is the first report 
demonstrating gender-based differences in ERα at the 
basal level thereby affecting the ratio of ER subtypes 
in the liver. Whether these differences in ER subtype 
expression at basal levels predispose males to severe 
and fast disease progression of HCV infection needs 
further investigation. 
We were able to detect ERα and ERβ transcripts in 
normal, HCV-related cirrhosis and HCV-related HCC 
groups. Similar observations were made in a Korean 
population study where they observed ERα and ERβ 
mRNA transcripts in more than 95% of HCV-related 
HCC liver tissues[40]. There was an increase of ERα and 
ERβ transcripts in diseased livers compared to normals 
but there were no changes in the protein levels of ERs 
among the groups in whole tissue lysates. However, 
gender analyses of ER expression in whole tissue 
lysates revealed that there was a significant decrease 
in ERα but not ERβ expression only in diseased male 
patients suggesting its disease specific role in these 
patients. These findings are in agreement with Villa 
et al who showed that there was reduction or even loss 
of wild-type ERα in male HCV-related HCC livers but an 
increase in the expression of variant ERα, which we have 
not evaluated[41,42]. 
Further, ER expression in the nuclear and cy-
toplasmic fractions from gender-pooled diseased livers 
differed when compared to normals. In the nuclear 
fraction, we found a higher expression of ERα and ERβ 
subtypes in HCV-mediated HCC and HCV-mediated 
cirrhosis tissues respectively compared to normal 
liver tissues, which is in contrast to the findings in the 
whole tissue extracts. HCV-mediated HCC tissues also 
showed significantly higher expression of cytoplasmic 
ERβ only when compared to HCV-cirrhosis tissues. 
We found a significant increase in the ERα to ERβ 
ratio in the cytoplasmic fraction than in the nuclear 
fraction of both HCV-related cirrhosis and HCV-related 
HCC livers as compared to normal livers. The clinical 
relevance of these changes in ER subtype expression 
in the subcellular compartments needs to be further 
investigated.  ER protein levels have been shown to 
vary under physiological states during breast tumor 
progression and hormonal therapy[43]. A recent 
study in the MCF7 cell-line has shown that estrogen 
stimulation involves dynamic changes in protein 
subcellular spatial distribution rather than changes in 
total protein abundance and propose that cells may 
be transformed by perturbations in nucleocytoplasmic 
shuttling of nuclear hormone receptors and other 
proteins[44,45]. In addition to breast cancer, ERs 
have also been implicated to play important roles 
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in gastrointestinal cancers like gastric, colon and 
colorectal cancers[46-48]. Since ERs primarily function 
as nuclear receptors and act as transcription factors 
for gene regulation, we propose that evaluating the 
expression of these proteins in cellular fractions as 
opposed to the whole tissue lysates would be a more 
accurate representation of their biological activity. 
Furthermore, our immunohistochemistry analysis also 
supported the increase in nuclear and cytoplasmic 
expression of ERα in both groups of diseased livers 
compared to normal livers (Supplementary Table 1). 
The expression of cytoplasmic ERβ was comparable 
among all the three groups by immunostaining. 
However, we observed a loss of nuclear ERβ in some 
HCC tissues (Supplementary Table 2). Loss of ERβ 
was also reported by Iavarone et al[39], who evaluated 
the expression of ER subtype mRNA in liver cancer 
tissues. Additionally, in breast, colon and prostate 
cancers, there are reports that indicate that presence 
of ERβ leads to better prognosis[49-52]. These findings 
about differential expression of nuclear or cytoplasmic 
ERβ expression in HCV cirrhosis or HCC can be sub-
stantiated only by increasing the sample size in the 
study.
Inflammation has been associated with the in-
itiation and progression of hepatocarcinogenesis[53]. 
Since HCV infection triggers inflammation, and chronic 
inflammation promotes carcinogenesis, NF-κB has 
been viewed as an important player in inflammation-
induced cancer[54,55]. In the current study, we found 
a significant increase in activated NF-κB in HCV-
related cirrhosis and in HCV-related HCC liver tissues. 
Significant increase in ERs in the cytoplasmic fraction 
of diseased livers may modulate the activity of pIKK 
thereby influencing the activation of NF-κB and 
inflammation outcome. ERα and NF-κB have been 
shown to directly interact in the nuclei of U2-OS cells 
treated with 17β-estradiol and aberrant ERα and NF-
κB expression correlated with invasion and metastasis 
in HCC[56,57]. 17β-estradiol, via ERα, can also inhibit 
the transport of p65 to the nucleus and downregulate 
inflammation[58]. Detailed mechanistic studies are 
warranted to explore the cross talk between ERα and 
NF-κB to unfold the nature of their interaction in a HCV 
infection setting.  
Unlike mammary carcinoma, the target genes 
and mechanism for ER regulation in liver are not well 
studied. There is a correlation between dysregulation 
in ER subtype with the overexpression of cyclin D1[59]. 
In our study, we observed increased expression of 
cyclin D1 in HCV-related cirrhosis and HCV-related 
HCC compared to normal livers and the expression 
of nuclear cyclin D1 correlated with the expression 
of nuclear ER subtypes in diseased livers. These 
findings along with other studies suggest that ERs 
may play a role in dysregulation of cellular proliferation 
by participating in increased transcription of cyclin 
D1 that aids in the progression of HCV infection to 
cirrhosis and eventually to hepatocellular carcinoma[60]. 
Cyclin D1 expression can also be regulated by ERα 
via non-genomic signaling. Treatment of HepG2 cells 
with 17β-estradiol activates the MAPK/ERK pathway 
by membrane-localized ERs resulting in increased 
expression of the cyclin D1 gene[61]. Apart from its 
role in cell cycle progression, cyclin D1 has recently 
been recognized to play a role in influencing sex 
steroid metabolism by increasing estrogen levels and 
decreasing androgen levels[62]. This is the first study 
that correlates the expression of ER subtypes with 
cyclin D1 in HCV-related cirrhosis and HCV-related 
HCC.
Increased expression of different isoforms or 
variants of ERα in diseased livers has been reported 
by mRNA studies and their involvement to activate 
oncogenic signaling pathways in cell lines has been 
reported[63,64]. The variants, ERα36 and ERα46 have 
been shown to modulate signaling pathways linked to 
proliferation and apoptosis[65, 66]. Differential expression 
of ERα36 has been observed in various cancers like 
breast, gastric, and endometrial cancer[67] and its 
expression correlates with a worse prognosis in breast 
cancer[68] but its role in HCV-mediated HCC has not 
been thoroughly investigated. Various ERβ variants 
have also been detected in different tissues but their 
role in carcinogenesis has not been evaluated as 
extensively as the ERα variants[69]. The present study 
focused to fill the gap in knowledge for the expression 
of wild type ERα and ERβ in normal and diseased 
livers. However, the expression of variant ER receptors 
also needs to be investigated to understand their role, 
if any, in HCV-related carcinogenesis. In addition to ER 
subtypes, the expression of androgen receptors should 
also be evaluated as HCV infection enhances androgen 
receptor-mediated signaling in an in vitro model[70] 
but it is not clear if androgen receptors play a role in 
carcinogenesis due to existing conflicting reports[71,72]. 
Finally, in the current study, we have demonstrated 
for the first time that the basal expression of wild-
type ERα in the liver is higher in males than females. 
Furthermore, the increased sub-cellular expression 
of ER subtypes observed in diseased livers correlates 
with the expression of inflammatory and oncogenic 
markers. This altered expression of ER subtypes in 
the liver may contribute to the progression of cirrhosis 
and cancer development during HCV-pathogenesis. 
These observations have been made in end stage 
HCV-related cirrhosis and HCC. In future, early disease 
or stage specific prospective longitudinal studies that 
include a larger sample size (in both males and females 
category) can be conducted to further clarify the role 
of nuclear or cytoplasmic ER expression at early stages 
of HCV-related cirrhosis or HCV-related HCC. Impact of 
gender associated ER subtype ratio distribution in the 
liver can also be studied relative to oncogenic markers 
and that may help us to monitor host therapeutic 
responses, viral clearance or improved prognosis 
during the carcinogenesis process. In conclusion, 
we expect that by evaluating the expression of sex 
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hormone receptors and understanding the signaling 
pathways they affect, gender and stage-related 
personalized therapies can be designed to treat and 
manage chronic HCV infections and HCV-related HCC. 
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COMMENTS
 Background
Hepatitis C virus (HCV) infection-related fibrosis and cirrhosis lead to the 
development of chronic liver disease that can ultimately result in hepatocellular 
carcinoma (HCC). According to epidemiological and clinical studies, chronic 
HCV infection mediated cirrhosis is more prevalent in males and progresses 
to cancer development faster as compared to premenopausal females who 
show better therapeutic responses and clear the infection. However, females 
with menopausal estrogen deficiency may have reactivation of the HCV 
infection resulting in accelerated progression to fibrosis and HCC development, 
confirming estrogen related etiology. Previous hormonal therapies in HCC 
have been inconclusive perhaps due to them poor understanding of estrogen 
receptor (ER) subtype expression in the normal livers from both males and 
females and also how changes in the expression of ERs may contribute to 
HCV-related disease progression. In the current study, they evaluated the basal 
liver ERα and ERβ expression in males versus females and have studied the 
changes in liver ER subtype expression and their correlation with inflammatory 
and proliferative markers in HCV-related cirrhosis and HCV-related HCC  
Research frontiers
Gender disparity in immunity to chronic infectious disease, autoimmunity and 
cancer development is increasingly being recognized in various clinical and 
experimental studies. Systemic estrogens in females play an important role 
in host innate immunity, however, the contributions of estrogen receptors are 
poorly recognized. In addition to hormonal cancers like breast, prostate and 
uterus, ER subtypes are being increasingly implicated in non-hormonal tissue 
cancers as well that include liver, colon, pancreas and stomach. 
Innovations and breakthroughs
This is the first report demonstrating gender-based differences in the basal 
expression of ERα in the liver that also results in change in ER subtype ratio. In 
addition to ER subtype expression in the whole liver tissue extracts, subcellular 
fractionation of liver extracts for expression of ER subtypes, inflammatory and 
proliferative markers in nucleus and cytoplasm of both, normal and diseased 
livers, were also evaluated. To our knowledge, this is the first study that 
correlates the expression of ER subtypes with cyclin D1 in livers of HCV-related 
cirrhosis and HCV-related HCC. 
Applications
Investigating gender associated changes in ER subtype ratio in the liver during 
the course of HCV-related disease progression along with oncogenic marker 
expression may help us to monitor gender specific host therapeutic responses, 
viral clearance and cancer development more effectively. Furthermore, these 
ER subtype expression studies will further complement existing treatments and 
pave the way to develop gender and stage-related personalized therapies that 
are highly needed to treat and manage chronic HCV infections and HCV-related 
HCC.
Terminology
Cirrhosis of the liver is damage caused by chronic Hepatitis C viral infection. 
Cirrhosis involves replacement of normal liver tissue with scar tissue that affects 
liver function and leads to end-stage disease.
Peer-review
Authors investigated ER expression in liver hepatocytes from normal subjects 
and patients with hepatitis C virus-related cirrhosis and Hepatocellular 
Carcinoma. The expression of ER subtypes, ERα and ERβ, were evaluated for 
the first time in relation to gender.
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